Biogen Idec (NASDAQ:BIIB)

biotech word cloud

Short Sellers Increase Bets in Major Biotechs

The short interest data are out for the August 15 settlement date. Companies within the biotech industry are considered a riskier group of stocks, with big potential upside and big ...
Read Full Story »
automatic inspection machine

Why Jefferies Sees 3 Big Biotechs Having Key Upside Catalysts Coming

After a year of being beaten down by legions of sellers, the biotech segment of the health care sector is finally starting to make a move back for investors, and the ...
Read Full Story »
automatic inspection machine

Short Sellers Run for Cover From Major Biotechs

The short interest data are out for the July 29 settlement date. Companies within the biotech industry are considered a riskier group of stocks, with big potential upside and big ...
Read Full Story »
money

Merrill Lynch Says the Time to Put Money Into Biotech Is Now

The Nasdaq Biotechnology Index has underperformed the broader market for some time. This year the index is still down about 13%, versus the 6% rise for the S&P 500. We ...
Read Full Story »
analysis

Top Analyst Upgrades and Downgrades: Biogen, Discovery Communications, Mosaic, Plains All American, Phillips 66, Rubicon Project and More

The stock market has pulled back from recent highs after several days of selling pressure. Shares were indicated lower by almost 0.2% for the Dow and S&P 500 on Wednesday ...
Read Full Story »
buy now

RBC Says Buy Big Biotechs Now for Possible Big 2016 Gains

We have talked about it for months here at 24/7 Wall St., and now many on Wall Street are talking about it as well. The selling in biotech, much of ...
Read Full Story »
baby boy's feet

How Biogen and Ionis Won Big (and Can Win More) From Late Stage Trial

Shares of Biogen Inc. (NASDAQ: BIIB) and, especially, Ionis Pharmaceuticals Inc. (NASDAQ: IONS) made handy gains early Monday morning following favorable interim results from a late-stage trial. The companies announced that nusinersen, ...
Read Full Story »
biotech word cloud

Major Biotechs See Increased Short Interest Bets

The short interest data are out for the July 15 settlement date. Companies within the biotech industry are considered a riskier group of stocks, with big potential upside and big ...
Read Full Story »
biotech word cloud

Short Sellers Become More Selective on Major Biotechs

The short interest data are out for the June 30 settlement date. Biotech companies are considered a riskier group of stocks, with big potential upside and big potential downside. In ...
Read Full Story »
automatic inspection machine

5 Top Biotechs Where Future Multi-Billion Dollar Drug Pipelines are Valued Almost at Zero

Sometimes market volatility and outside shocks create a rift between market prices and real value. That may currently be the case in the largest stocks in the biotech sector within health ...
Read Full Story »
biotech word cloud

Short Sellers Run for Cover From Major Biotechs

The short interest data are out for the June 15 settlement date. Biotech companies are considered a riskier group of stocks, with big potential upside and big potential downside. After ...
Read Full Story »
Stock Price

Verifone, Biogen Crash Wednesday’s 52-Week Low Club

June 22, 2016: Here are four stocks trading with relatively heavy volume among 40 equities making new 52-week lows in Wednesday's session. NYSE decliners led advancers by 5 to 4 ...
Read Full Story »
hammered

7 Biopharma Companies That Destroyed Shareholders Last Week

This past week was perhaps one of the biggest of the year for the biopharmaceuticals industry. While there were some winners — a few resulting for the American Society of ...
Read Full Story »
biotech word cloud

Short Sellers Become More Selective on Major Biotechs

The short interest data are out for the May 31 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
clinical trials

Biogen Stumbles Over Missed Mid-Stage Results

Shares of Biogen Inc. (NASDAQ: BIIB) slumped early in Tuesday’s session following the release of less-than-favorable top-line results from its mid-stage clinical study. This was part of the company’s Synergy ...
Read Full Story »